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of about 25,000 hospitalizations from 180,000 diabetic patients were analyzed over a 
five year period. Results: Study population of statutorily insured diabetic patients 
is representative as it is comparable to the overall German population by age, gender, 
mortality and morbidity. Treatment of most diabetic patients on oral anti-diabetic 
drugs remained unchanged before and after a hospital stay (55.8%). A smaller part of 
diabetic patients (37.6%) is admitted and discharged with the same insulin regimen. 
In 15% of the cases where patients are discharged with insulin, insulin treatment 
was initiated or changed during hospitalization. 53% of these patients received a 
first prescription of insulin. Basal supported oral therapy (BOT) and conventional 
insulin treatment (CT) regimens made up the largest fraction of all insulin initiations 
(62%). If a BOT was initiated, insulin glargine was favored (60%) compared to all other 
long acting insulin formulations such as human insulin (30%) and insulin detemir 
(10%). In 21% of the cases initiation results in a basal-bolus regimen (ICT) and in 
17% in a prandial insulin therapy (SIT). ConClusions: Insulin treatment was first 
prescribed or switched during hospitalization in 15% of the cases where patients 
are discharged with insulin. Initiation of BOT and CT regimens turned out to be the 
overall preferred therapies in the underlying analysis. Given the fact that 26.7% of 
the German diabetic population has suboptimal HbA1c-values more of them should 
receive an adequate adjustment of antidiabetic therapy during hospitalization.
PDB122
TreaTmenT PaTTerns anD BurDen of Illness of CushIng’s DIsease In 
The unITeD KIngDom: real WorlD (rW) DaTa from ClInICal PraCTICe 
researCh DaTalInK (CPrD)
Murray R.D.1, Forsythe A.2, Siva V.3, Oliver N.3, Rojas-Farreras S.4, Roset M.4
1Leeds Teaching Hospitals NHS Trust, West Yorkshire, UK, 2Novartis Oncology, Florham Park, NJ, 
USA, 3Novartis Pharmaceuticals UK Limited, GB- Frimley/Camberley, Surrey, UK, 4IMS Health, 
Barcelona, Spain
objeCtives: Cushing’s disease (CD) is an extremely debilitating endocrine condition 
caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma. 
CD has a significant impact on patients’ health, as well as on their physical, cogni-
tive, emotional, and social well-being. Treatment of CD is complex involving sur-
gery, radiotherapy and medication; however, there are limited published real world 
data on treatment patterns. Methods: A retrospective database analysis study 
using CPRD linked with Hospital Episode Statistics (HES) was conducted. Patient 
population included patients enrolled after January 1956 up to March 2012 with at 
least two CD diagnosis or Cushing’s Syndrome diagnosis and one of the following: 
transsphenoidal surgery, benign pituitary neoplasm or pituitary disorder. Data was 
collected from 510 general practitioners (GPs). Patients’ characteristics, treatment 
history, and comorbidities were analysed. Cortisol values (urinary free or serum) 
were expressed as ULN-fold based on patient specific lab norms. Standardized 
Mortality Ratio (SMR) was calculated and compared to general age/gender matched 
UK population. Results: A total of 258 patients with CD were identified (227 alive 
and 31 dead) ). Among alive patients, mean age (SD) was 54(15) years old, 76% female, 
mean age at diagnosis was 38(15). Comorbidities were: infections (63%), hyperten-
sion (47%), fractures (30%), depression (25%), diabetes mellitus (22%), osteoporosis 
(22%) and obesity (18%); 65% of patients had treatment records. Among those: 48% 
received TSS, 41% adrenalectomy, 24% radiotherapy and 42% oral medications. A 
total of 32% of 1stline TSS and 34% of 1stline radiotherapy patients received further 
treatment; 26% of adrenalectomy patients were treated with radiotherapy and/
or surgery for Nelson’s syndrome. Among patients on oral medications, majority 
received metyrapone (79%) or ketoconazole (32%). 69% of patients with cortisol 
measurements (n= 92) were not controlled. SMR was 7.4, 5.1 and 3.1 at 5, 10 and 15 
years respectively. ConClusions: This study demonstrated significant mortality 
and morbidity burden of CD in the UK primary practice.
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objeCtives: To critically appraise current evidence on the cost-effectiveness (CE) 
of therapeutic education for people with type 2 diabetes (T2D) and prediabetes 
compared to usual care. Methods: We conducted a systematic review of eco-
nomic evaluations of educational programs for people with T2D or prediabetes 
which were based on randomized controlled trials and published between 2002 
and 2012. The quality of the clinical and the health economic evidence was ranked 
high, moderate, low or very low after critical appraisal by means of the Cochrane 
Collaboration’s tool for assessing risk of bias and the Consensus Health Economic 
Criteria List. Interventions were classified based on the reported incremental 
cost-effectiveness ratios (ICERs). Results: The search yielded 1.886 publications. 
Fourteen met the inclusion criteria. In prediabetes, patient education was found 
to be cost-saving in two out of five studies. The reported ICERs were € 850; € 24.400; 
€ 110.850 per quality adjusted life-year (QALY) gained from the payer’s perspec-
tive and € 6.800; € 40.000; € 48.500 per QALY gained from the societal perspective. 
In T2D, the CE of patient education varied from cost-saving to not cost-effective 
and had a mean ICER of € 44.500 (range: € 6.380; € 83.000) per QALY gained from 
the payer’s perspective. The quality of the health economic evidence was mainly 
moderate or low in studies on prediabetes, and very low in studies on T2D. The 
uncertainty analysis were not exhaustive in most studies. In the modeling stud-
ies (n = 10), the models’ structural assumptions and validation methods were in 
general not properly reported. ConClusions: Current evidence on CE of thera-
peutic education of people with prediabetes and T2D is limited in volume and 
quality but consistently suggests that investing in patient education may offer 
good value for money. Studies of better quality are needed to reconfirm these 
findings. Commonly accepted methodologies for performance and assessment 
of health economic evaluations should guide further research.
47% (-21%) and 22% to 16% (-6%), respectively. ConClusions: For Product A, after 
the regulation update, prescription rate for w-biguanides is decreased, while that 
for w-sulphonylurea and monotherapy options are increased. However, for Product 
B, prescription rate for w-sulphonylurea is decreased, while those for w-biguanides 
and monotherapy options are increased. For both products, prescription rate for 
monotherapy is increased. Limitation of this study is level of comprehensiveness for 
the system variables (market dynamics, patient profiles, etc.) This study concludes 
that, regardless regulation updates, there is an unmet need, which results in physi-
cians’ preference of innovative treatment options in clinical practice for treatment 
of Diabetes. *ProductA= Sitagliptin, **ProductB= Vildagliptin
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objeCtives: 1) International reference pricing (IRP) is a complex cost containment 
policy which has an often unclearly defined ripple effect across countries; 2) The 
aim of this study was to quantify by simulation what the ripple effect through IRP 
would be if prices of DPP-IV inhibitors in Germany dropped post-AMNOG benefit 
assessment because of either internal referencing or subject to the specific AMNOG 
provisions under which the IRP process can be deployed; and 3) A secondary objec-
tive was to draw initial conclusions over the evolution of IRP. Methods: 1) The IRP 
landscape was studied using primary and secondary payer research on the basket of 
countries formally or informally employed in 40 countries, specifying a) those which 
reference Germany directly and b) identifying a cascading “indirect wave” of those 
which reference the countries that reference Germany, and 2) We examined current 
pharmaceutical pricing data and employed an industry validated proprietary simu-
lation model for assessing the impact of selected AMNOG-triggered price decline 
scenarios. Results: 1) In the universe of 32 countries where the 2 DPP-IV inhibitors 
studied are on the market, 25 countries are potentially affected by a price decrease in 
Germany: 16 countries that reference Germany directly and 9 via a secondary phase 
of IRP, and 2) The resulting interdependent price impact - solely from IRP - in the 
diverse afflicted countries is quantified for each model scenario. ConClusions: 
1) As more countries explore the possibility or already deploy IRP as a pricing poli-
cies, it will become increasingly crucial for pharmaceutical companies to gauge 
the full impact of evolving international referencing and cross-referencing – and 
integrate this early on in their pricing strategy; 2) The results demonstrate that he 
composition itself of the basket of reference countries is driving the pricing impact; 
and 3) IRP and value-based or market pricing could be complementary and need 
not necessarily be diametrically opposed.
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objeCtives: Acromegaly is a rare slowly progressing endocrine disorder character-
ized by abnormally elevated levels of growth hormone (GH) and insulin-like growth 
factor-1 (IGF-1). Acromegaly has a significant impact on patients’ health, as well as 
on their physical, cognitive, emotional, and social well-being. Treatment of acro-
megaly is complex involving surgery, radiotherapy and medication; however, there 
are limited published real world data on treatment patterns. Methods: A retro-
spective database analysis study using CPRD linked with Hospital Episode Statistics 
(HES) was conducted. Patient population included patients enrolled between January 
1956 and March 2012 with Acromegaly diagnosis at two timepoints or Acromegaly 
diagnosis and either GH or IGF-1 test. Data was collected from 500 general practi-
tioners (GPs). Patients’ characteristics, treatment history, comorbidities and disease 
control were analysed. Biochemical control was defined as an age/gender adjusted 
IGF-1≤ ULN and GH≤ 2.5mg/l. Standardized Mortality Ratio (SMR) was calculated 
and compared to general age/gender matched UK population. Results: A total 
of 822 patients with Acromegaly were identified (580 alive and 242 dead at March 
2012). Among alive patients, mean age (SD) was 63(15) years old, 52% male, mean 
age at diagnosis was 48(14). Comorbidities included: hypertension (46%), osteopo-
rosis (31%), arthralgia/synovitis (21%), diabetes (18%), carpal tunnel (13%) and sleep 
apnea (11%); 31% of patients had no treatment records. Among treated patients: 38% 
received TSS, 29% radiotherapy, 45% somatostatin analogs (SSAs), and 45% dopamine 
agonists (DAs). A total of 45% of TSS 1st line and 52% of radiotherapy 1st line patients 
received further treatment; 22% of SSAs patients and 34% of DAs patients switched 
to/added 2nd line medical therapy. 64% of patients with GH+IGF-1 data (n= 109) 
were not controlled. SMR was 4.6, 3.4 and 2.5 at 5, 10 and 15 years after diagnosis 
respectively. ConClusions: This study demonstrated significant mortality and 
morbidity burden of Acromegaly in the UK GP practice.
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objeCtives: One important aspect for patients suffering from diabetes is an appro-
priate metabolic control to avoid micro- and macrovascular complications. There is 
a lack of information about adjustment of antidiabetic treatment during hospitali-
zation. Methods: To identify a change in medication in patients suffering from 
diabetes, treatment regimens before and after hospitalization were investigated 
retrospectively. Information was taken from 2006 to 2010 German claims data. Data 
